Mark Levis, MD
Medical Oncology · Baltimore, MDNPI 1578507976
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $231,698 of the $322,864 with a category attached, or 71.8%. It is spread thinly across 22 manufacturers, the largest accounting for just 15.7%. Among medical oncology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $1773.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Inc$51K
- Daiichi Sankyo Inc.$38K
- Astellas Pharma Europe Ltd$35K
- Astellas Pharma US Inc$34K
- Agios Pharmaceuticals, Inc.$26K
- AbbVie$25K
- plus $113K from 16 others
Across 319 payments — averaging $12,313 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$1.9M
- Astellas Pharma Global Development$751K
- Amgen$583K
- Sumitomo Pharma America, Inc.$438K
- AbbVie$174K
- National Marrow Donor Program$35K
- plus $5K from 2 others
What the payments were for
- Consulting fees$231,69872%
- Speaking & faculty fees$19,8366%
- Travel & lodging$51,26316%
- Food & beverage$4,2031%
- Education$15,8645%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Inc | 16 | $50,716 |
| Daiichi Sankyo Inc. | 34 | $38,250 |
| Astellas Pharma Europe Ltd | 6 | $35,243 |
| Astellas Pharma US Inc | 31 | $33,945 |
| Agios Pharmaceuticals, Inc. | 17 | $26,110 |
| AbbVie | 26 | $25,330 |
| Amgen | 15 | $23,220 |
| E.r. Squibb & Sons, L.L.C. | 2 | $17,940 |
| Gilead | 7 | $11,161 |
| GSK | 5 | $10,075 |
| Astellas Pharma Global Development | 2 | $7,744 |
| Jazz Pharmaceuticals Inc. | 2 | $7,360 |
| Bristol Myers Squibb | 5 | $7,157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $6,440 |
| Sumitomo Pharma America, Inc. | 2 | $6,020 |
| Otsuka Pharmaceutical Co., Ltd. | 2 | $4,800 |
| F. Hoffmann-la Roche AG | 2 | $3,500 |
| Janssen Scientific Affairs, LLC | 2 | $2,517 |
| Novartis | 1 | $2,400 |
| Genentech USA, Inc. | 1 | $1,980 |
| Syndax Pharmaceuticals, Inc. | 1 | $800 |
| National Marrow Donor Program | 1 | $156 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$322,864 in reported general payments places this provider in the 95th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XospataGilteritinib Fumarate | 92 | $2,282,219 |
| TibsovoIvosidenib | 48 | $1,513,922 |
| IdhifaEnasidenib Mesylate | 28 | $893,997 |
| VenclextaVenetoclax | 31 | $177,430 |
| SprycelDasatinib | 24 | $118,035 |
| ValacyclovirValacyclovir Hcl | 108 | $6,067 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $426 |
| Tramadol Hcl | 39 | $310 |
| Pantoprazole Sodium | 23 | $253 |
| Levofloxacin | 11 | $245 |
| Famotidine | 24 | $237 |
| Tamsulosin Hcl | 13 | $222 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $170 |
| SynthroidLevothyroxine Sodium | 11 | $126 |
| Metoprolol Succinate | 14 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXospata | $33,945 | $2,282,21992 claims |
| Bristol Myers SquibbIdhifa | $7,157 | $893,99728 claims |
| AbbVieVenclexta, Synthroid | $25,330 | $177,55642 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $17,940 | $118,03524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
- Julie BrahmerBaltimore$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.